SHANGHAI, July 13 — The question that has quietly nagged at the pharmaceutical industry for years is whether artificial intelligence can actually discover new drugs, or whether it is just another expensive way to generate dead ends. A deal signed earlier this month between CSPC Pharmaceutical Group and AstraZeneca suggests the industry is betting on the former. The collaboration, announced on July 2, gives AstraZeneca access to CSPC’s proprietary AI molecular design platform.
The two companies will use the system to jointly discover and develop new drugs. It is a concrete example of how the industry’s long-standing fascination with AI is now translating into real partnerships.
The mechanism behind the deal
CSPC’s platform is designed to do something that has historically been slow and expensive: propose new molecules that might work as medicines. Traditional drug discovery involves screening vast libraries of compounds, testing them in assays, and then iterating on the ones that show promise. The AI platform, by contrast, attempts to predict which molecular structures are most likely to be both effective and safe, cutting down the number of dead ends before a candidate ever reaches a lab.
What researchers found, and what made this deal possible, is that the platform has matured enough for a major player like AstraZeneca to commit to using it as a core part of its discovery pipeline. The deal does not specify which diseases or therapeutic areas the two companies will target first.
Industry momentum
This is not an isolated experiment. The CSPC-AstraZeneca deal comes at the end of a record first half of 2026 for the pharmaceutical sector. According to Lan Gongtao, the first six months of the year saw 81 deals totalling US$110 billion across 10 therapeutic areas.
That is a remarkable pace of dealmaking, and it signals that companies are aggressively reshuffling their portfolios and betting on new technologies. China now accounts for 30% of new drugs under development globally, Lan Gongtao said.
That figure puts the country at the centre of the industry’s future pipeline, and it helps explain why a Chinese firm like CSPC is now partnering with a British-Swedish giant like AstraZeneca. The collaboration is as much about accessing Chinese AI capabilities as it is about accessing Chinese drug discovery.
What to watch next
The obvious question is whether the molecules that emerge from this partnership will actually make it to patients. AI-designed drugs have not yet produced a blockbuster, and the field is still young. But the sheer volume of capital flowing into these deals suggests that the industry is willing to wait.
The CSPC-AstraZeneca collaboration will be one to watch as a test case for whether AI molecular design can deliver on its promise.
